HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $37 price target.
February 29, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Viridian Therapeutics with a $37 price target.
The reiteration of a Buy rating and maintenance of a $37 price target by a reputable analyst could positively influence investor sentiment towards VRDN, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100